UNSPSC 51323105: Disogluside

This classification denotes an anti-lipidemic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8KI671F2NS. European Medicines Agency schedules Disogluside in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07236MIG. Disogluside generally arises in the molecular formula C33H52O8. The term DISOGLUSIDE is an International Non-Proprietary Name or INN. DISOGLUSIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule disogluside under HS 29389090 and SITC 54161. As of Q4 2014, DISOGLUSIDE remains the US FDA Preferred Term for this commodity. Disogluside bears US NLM identifiers UMLS ID C2699784 and NCI Concept Code C78057. SMILES: O1C2C(C3(C(C4C(CC3)C3(C(=CC4)CC(OC4OC(C(O)C(O)C4O)CO)CC3)C)C2)C)C(C21OCC(CC2)C)C.

UNSPSC 51323105 Disogluside is a Commodity code designating a specific pharmaceutical active ingredient, though recent state and local solicitations tagged with this code actually procure a broader range of emergency medications and generic pharmaceuticals rather than disogluside specifically. State and local governments buying under this code seek sealed supplies of advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products for fire rescue operations, state health agency programs, and cooperative purchasing networks serving multiple jurisdictions. Issuing bodies include municipal fire departments (via city purchasing offices), state health commissions, and multistate cooperative purchasing alliances. The work involves supplying finished pharmaceutical products that meet FDA requirements, maintain specified shelf life and expiration-date thresholds (typically nine months to one year minimum from acceptance or manufacture), comply with Good Manufacturing Practices and Drug Supply Chain Security Act standards, and include Safety Data Sheets and accessibility documentation per OSHA Hazard Communication Standards and Section 508 requirements.

Recent opportunities span Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications to supply Tampa Fire Rescue with 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with bids due April 8, 2026, and an estimated contract value of $40,000.00 under a one-year term with two optional one-year renewals and three discretionary 30-day extensions, featuring a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 for Generic Multi-Source Pharmaceuticals and OTC Products with proposals due March 26, 2026, requiring vendors to supply through AmerisourceBergen, Cardinal Health, and Morris & Dickson with pricing weighted 75 percent on competitiveness, products effective July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on March 27, 2026, seeking vendor capabilities for a Direct-to-Manufacturer Prescriptions program to inform future formal procurement strategy, with responses due April 3, 2026.